RHYTHM PHARMACEUTICALS, INC. (RYTM) Debt-to-equity % [USD] 2018 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rhythm Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from 2018 to 2024.
  • Rhythm Pharmaceuticals, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 105 %, a 133% increase year-over-year.
Debt-to-equity, Quarterly (% [USD])
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 105 +60.2 +133% Mar 31, 2024
Q4 2023 74.5 +37.9 +103% Dec 31, 2023
Q3 2023 61.2 +32.6 +114% Sep 30, 2023
Q2 2023 50.7 +30.4 +150% Jun 30, 2023
Q1 2023 45.2 +31.4 +228% Mar 31, 2023
Q4 2022 36.6 +24.9 +213% Dec 31, 2022
Q3 2022 28.6 +17.8 +164% Sep 30, 2022
Q2 2022 20.2 +9.56 +89.5% Jun 30, 2022
Q1 2022 13.8 +3.68 +36.4% Mar 31, 2022
Q4 2021 11.7 +2.52 +27.4% Dec 31, 2021
Q3 2021 10.8 +1.99 +22.6% Sep 30, 2021
Q2 2021 10.7 +0.3 +2.89% Jun 30, 2021
Q1 2021 10.1 -2.15 -17.5% Mar 31, 2021
Q4 2020 9.2 -2.98 -24.5% Dec 31, 2020
Q3 2020 8.82 -2.19 -19.9% Sep 30, 2020
Q2 2020 10.4 +3.02 +41.1% Jun 30, 2020
Q1 2020 12.3 +7.8 +175% Mar 31, 2020
Q4 2019 12.2 +8.4 +222% Dec 31, 2019
Q3 2019 11 +7.62 +224% Sep 30, 2019
Q2 2019 7.35 +2.29 +45.2% Jun 30, 2019
Q1 2019 4.46 Mar 31, 2019
Q4 2018 3.78 Dec 31, 2018
Q3 2018 3.39 Sep 30, 2018
Q2 2018 5.06 Jun 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.